These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8180743)

  • 1. Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan.
    Kubo SH
    Coron Artery Dis; 1994 Feb; 5(2):119-26. PubMed ID: 8180743
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
    Fitton A; Brogden RN
    Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
    Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Levosimendan].
    Michels G; Herzig S; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
    [No Abstract]   [Full Text] [Related]  

  • 6. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
    Duncker DJ; Verdouw PD
    Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
    [No Abstract]   [Full Text] [Related]  

  • 7. Pimobendan has a potent venodilating action in patients with congestive heart failure.
    Matsumoto A; Momomura S; Yokoyama I; Aoyagi T; Sugiura S; Omata M
    Cardiovasc Drugs Ther; 1998 Dec; 12(6):595-7. PubMed ID: 10410829
    [No Abstract]   [Full Text] [Related]  

  • 8. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
    Rasmussen T; Schmidt H
    Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vasoactive and inotropic drugs in acute heart failure].
    Ruiz-Laiglesia FJ; Camafort-Babkowski M
    Med Clin (Barc); 2014 Mar; 142 Suppl 1():49-54. PubMed ID: 24930084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of pimobendan in the management of heart failure.
    Fuentes VL
    Vet Clin North Am Small Anim Pract; 2004 Sep; 34(5):1145-55. PubMed ID: 15325474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the in vivo mechanism of action of levosimendan?
    MacGowan GA
    J Card Fail; 2005 Aug; 11(6):482; author reply 482-3. PubMed ID: 16105641
    [No Abstract]   [Full Text] [Related]  

  • 12. Levosimendan in regional myocardial ischemia.
    Pieske B
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):379-81. PubMed ID: 12656119
    [No Abstract]   [Full Text] [Related]  

  • 13. Inotropic agents and immune modulation.
    Sasayama S
    Cardiovasc Drugs Ther; 2002 May; 16(3):237-43. PubMed ID: 12374902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The novelty in the treatment of heart failure].
    Reingardiene D
    Medicina (Kaunas); 2005; 41(7):625-31. PubMed ID: 16062032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
    Colucci WS; Wright RF; Braunwald E
    N Engl J Med; 1986 Feb; 314(6):349-58. PubMed ID: 2418353
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan.
    Tsuda T; Izumi T; Kodama M; Hanawa H; Takahashi M; Suzuki M; Aizaki T; Uchiyama H; Kuwano H; Shibata A
    Jpn Heart J; 1992 Mar; 33(2):193-203. PubMed ID: 1593749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the pharmacology and clinical uses of pimobendan.
    Boyle KL; Leech E
    J Vet Emerg Crit Care (San Antonio); 2012 Aug; 22(4):398-408. PubMed ID: 22928748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effects of calcium-sensitizing agents.
    Vegh A; Papp JG; Udvary E; Kaszala K
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S20-31. PubMed ID: 8907128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phosphodiesterase inhibition as a new positive-inotropic principle].
    Hartmann A; Saeed M; Sütsch G; Bing RJ
    Dtsch Med Wochenschr; 1986 Dec; 111(51-52):1971-7. PubMed ID: 3539571
    [No Abstract]   [Full Text] [Related]  

  • 20. Inotropic effects of a single intravenous recommended dose of pimobendan in healthy dogs.
    Hori Y; Taira H; Nakajima Y; Ishikawa Y; Yumoto Y; Maekawa Y; Oshiro A
    J Vet Med Sci; 2019 Jan; 81(1):22-25. PubMed ID: 30404952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.